Status:
COMPLETED
Identification of Integrin ab Expression in Lung Cancer Patients
Lead Sponsor:
Korea University Guro Hospital
Conditions:
Expression of Integrin ανβ3 in Lung Cancer
Eligibility:
All Genders
20-80 years
Brief Summary
It has been reported that the expression rates of integrin αvβ3 and integrin αvβ5 in NSCLC are 89% and 100%, respectively. Among RGD (Arg-Gly-Asp) peptides, cRGDyK peptide (cRGD) known as integrin ανβ...
Detailed Description
Patient samples: From the Human Resource Bank of the Institute of Pathology, Korea University, the investigators collected paraffin-embedded tissue sections from 61 patients with NSCLC (adenocarcinoma...
Eligibility Criteria
Inclusion
- NSCLC (adenocarcinoma or squamous cell carcinoma) who had undergone surgical treatment for NSCLC at Korea University Guro Hospital between 2015 and 2018
Exclusion
- patients had undergone perioperative chemo- or radiotherapy
Key Trial Info
Start Date :
December 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 25 2021
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT06167941
Start Date
December 19 2019
End Date
November 25 2021
Last Update
December 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital
Seoul, South Korea, 08308